A randomised control study to compare the efficacy of oral tofacitinib versus oral corticosteroids as mini pulse therapy in the treatment of patients with unstable vitiligo

Department of Dermatology, venereology, Leprology0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年11月21日

试验速览

暂无简介。

•Consecutive patients with a clinical diagnosis of non-segmental vitiligo
•Patients with actively progressing vitiligo with or without prior treatment history
•Body surface area >10%
•Patients of either sex with age 18-60 years
•Wash out period of 4 weeks if on prior topical or systemic therapy

•Stable disease i.e., no koebnerisation, no new lesions or increase in size of lesions, well demarcated borders, no satellite or confetti lesions.
•Segmental vitiligo, focal or mucosal vitiligo
•Age < 18 years or > 60 years.
•Leukoderma secondary to other causes e.g., chemical leukoderma
•Pregnancy/Lactation.
•Patients with severe hepatic, renal or other systemic disorder
•Uncontrolled hypertension and diabetes mellitus
•Pre-existing malignancy.
•Immunosuppressed patients • Patients with concomitant infections like tuberculosis, systemic deep fungal infections, viral hepatitis, HIV, COVID-19 etc.
•Hematological abnormalities: Absolute lymphocyte count <500/mm3 or absolute neutrophil count (ANC) <1000/mm3 or hemoglobin <9 g/dL
•Known hypersensitivity to JAK-STAT inhibitors
•Patients who do not give consent for participation in the study
•Patients with unrealistic expectations

发起方

Department of Dermatology, venereology, Leprology